Key result
Anakinra was successfully used to treat a 44-year-old male with recurrent pericarditis.
Why the study?
In patients with corticosteroid-dependent and corticosteroid-resistant pericarditis, several steroid-sparing options like anakinra are being recently tried.
Does anakinra improve symptoms in a patient with steroid-dependent recurrent pericarditis?
Case Report (n=1)
Does anakinra improve symptoms in a patient with steroid-dependent recurrent pericarditis?
Anakinra may be an effective steroid-sparing treatment option for patients with corticosteroid-dependent recurrent pericarditis.
Answers are grounded in this paper and cite their sources.
May support anakinra consideration in recurrent pericarditis; hypothesis-generating case report requiring randomized confirmation.
Non-steroidal anti-inflammatory drugs and colchicine are the cornerstone treatment for recurrent pericarditis. Corticosteroids are frequently used in patients with recurrent episodes of pericarditis. In patients with corticosteroid dependent and corticosteroid-resistant pericarditis, several steroid-sparing options like azathioprine, intravenous immunoglobulin (IVIG), and anakinra are being recently tried. In this article, we present the case of a 44-year-old male with recurrent pericarditis, who was successfully treated with anakinra.Abbreviations: Non-steroidal anti-inflammatory drugs, NSAIDS; Aspirin, ASA; Erythrocyte sedimentation rate, ESR; Serum Protein Electrophoresis, SPEP; Magnetic Resonance Imaging, MRI; C-Reactive Protein, CRP; Aspartate Aminotransferase, AST; Alanine Aminotransferase, ALT; Idiopathic recurrent pericarditis, IRP; Intravenous Immunoglobulin, IVIG.
No takes yet. Share an insight, caveat, or question.
Thallapally et al. (2021) conducted a case report in Recurrent pericarditis (n=1). Anakinra was evaluated. Anakinra was successfully used to treat a 44-year-old male with recurrent pericarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: